Salivary gland cancers (SGCs) are rare, accounting for less than 5% of all malignancies of
the head and neck region, and are morphologically heterogeneous. The diagnosis is mainly …

Abstract Salivary Gland carcinomas (SGCs) are rare tumors accounting for less than 1% of
all cancers with 21 histologically diverse subtypes. The rarity of the disease presents a …

Background Immunotherapies targeting immune checkpoints have gained increasing
attention in cancer treatment, emphasizing the need for predictive biomarkers. Circular …

Purpose: There is a significant need for effective therapies to treat recurrent/metastatic (R/M)
adenoid cystic carcinoma (ACC). This study evaluated the multitargeted VEGFR tyrosine …

Although immune checkpoint inhibitors (ICIs) are effective in some patients with salivary
gland carcinoma (SGC), biomarkers which predict the efficacy and prognosis of SGC …

Background Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and
programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in …

Salivary gland carcinomas (SGCs) are highly heterogeneous histopathologi cal entities that
arise in either the ma jor or minor salivary glands. Although uncommon, these tumours …

Introduction Recurrent or metastatic adenoid cystic carcinoma (ACC) of the head and neck is
rare and highly aggressive. Due to the ineffectiveness of immune checkpoint therapies, this …

Background Treatment of salivary gland tumors (SGTs) remains challenging. Little is known
about the immune landscape of SGTs. We aimed to characterize the tumor …

Simple Summary The efficacy of immunotherapies in salivary gland cancer (SGC) remains
controversial. To optimize immunotherapy, understanding the tumor microenvironment …